PMID- 26965676
OWN - NLM
STAT- MEDLINE
DCOM- 20171010
LR  - 20181202
IS  - 1532-2750 (Electronic)
IS  - 1098-612X (Linking)
VI  - 18
IP  - 11
DP  - 2016 Nov
TI  - Confirmatory field study for the evaluation of ciclosporin at a target dose of 
      7.0 mg/kg (3.2 mg/lb) in the control of feline hypersensitivity dermatitis.
PG  - 889-897
LID - 10.1177/1098612X16636660 [doi]
AB  - Objectives This study was designed to confirm the efficacy and tolerability of a 
      daily dose of 7.0 mg/kg (3.2 mg/lb) ciclosporin (CsA) in the treatment of feline 
      hypersensitivity dermatitis (HD), as this includes some of the most frequently 
      suspected skin diseases in cats and recent publications have reported the 
      successful use of CsA in the treatment of feline HD. Methods In total, 217 cats 
      with feline HD were treated daily for 42 days with a target dose of 7 mg/kg CsA 
      (n = 144) or a placebo control (n = 73) administered either in the food or 
      directly in the mouth following feeding. Clinical and dermatological evaluations 
      were conducted on days 0, 21 and 42, or study exit. Safety was evaluated through 
      physical examinations, clinical pathology and the monitoring of adverse events 
      (AEs). Results Administration of CsA at 7.0 mg/kg produced a significant 
      improvement in the total lesion score ( P <0.0001). The average reduction from 
      visit 1 to visit 3 was 65.1% in the CsA group (9.2% for the placebo). In 
      addition, owners assessed 78.3% of the cases in the CsA group as a success. 
      Statistically significant recoveries were also seen in extent of lesions, 
      investigator assessment of overall improvement, and mean improvement in both the 
      investigators' and owners' assessment of pruritus. Mild gastrointestinal 
      disorders were the most common AEs but did not require cessation of therapy. 
      Conclusions and relevance Results confirm that 7.0 mg/kg CsA dosed daily in food 
      or orally for up to 6 weeks is effective and well tolerated by cats with feline 
      HD.
FAU - Roberts, Elizabeth S
AU  - Roberts ES
AD  - 1 Novartis Animal Health US, Greensboro, NC, USA.
FAU - Speranza, Cindy
AU  - Speranza C
AD  - 2 Novartis Animal Health, Basel, Switzerland.
FAU - Friberg, Cecilia
AU  - Friberg C
AD  - 3 Animal Dermatology Center of Chicago, Chicago, IL, USA.
FAU - Griffin, Craig
AU  - Griffin C
AD  - 4 Animal Dermatology Clinic, San Diego, CA, USA.
FAU - Steffan, Jean
AU  - Steffan J
AD  - 2 Novartis Animal Health, Basel, Switzerland.
FAU - Roycroft, Linda
AU  - Roycroft L
AD  - 1 Novartis Animal Health US, Greensboro, NC, USA.
FAU - King, Stephen
AU  - King S
AD  - 1 Novartis Animal Health US, Greensboro, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20160709
PL  - England
TA  - J Feline Med Surg
JT  - Journal of feline medicine and surgery
JID - 100897329
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
SB  - IM
MH  - Animals
MH  - Canada
MH  - Cat Diseases/*drug therapy/pathology
MH  - Cats
MH  - Cyclosporine/administration & dosage/*therapeutic use
MH  - Dermatitis, Atopic/drug therapy/*veterinary
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Immunosuppressive Agents/administration & dosage/*therapeutic use
MH  - Male
MH  - Pruritus/drug therapy/veterinary
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - United States
EDAT- 2016/03/12 06:00
MHDA- 2017/10/11 06:00
CRDT- 2016/03/12 06:00
PHST- 2016/03/12 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
PHST- 2016/03/12 06:00 [entrez]
AID - 1098612X16636660 [pii]
AID - 10.1177/1098612X16636660 [doi]
PST - ppublish
SO  - J Feline Med Surg. 2016 Nov;18(11):889-897. doi: 10.1177/1098612X16636660. Epub 
      2016 Jul 9.